AstraZeneca, the British multinational pharmaceutical and biopharmaceutical company, who are working with the University of Oxford and are the third participant in the race to develop a vaccine, is also in phase three of clinical trials presently. The results of the Oxford University/AstraZeneca vaccine trials will be published before Christmas. More than 20,000 volunteers are participating in trials for the Oxford University/AstraZeneca vaccine, in countries including the UK, South Africa, Brazil and Kenya. The vaccine trial team are optimistic that data on its safety and efficacy of the vaccine will be available by the end of the year. The Oxford University/AstraZeneca vaccine, called ChAdOx1 nCoV-19, uses a weakened version of a common cold virus (adenovirus) which causes infections in chimpanzees.